https://www.selleckchem.com/pr....oducts/Mycophenolic-
The patient continued to respond to afatinib treatment (30 mg once daily) with minimal adverse effects. This is the first case report of clinical improvement after afatinib treatment in a patient with lung adenocarcinoma and leptomeningeal metastasis harboring an EGFR complex mutation (exon19del+K754E), and thus provides a clinical reference for treatment with afatinib of cancers harboring EGFR compound mutations. This is the first case report of clinical improvement after afatinib treatment in a patient with lu
Beğen
Yorum Yap
Paylaş
